CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0972 (clinicaltrials.gov NCT No: NCT01198067)
Title:Phase I Study of Pomalidomide in relapsed or refractory Waldenstrom Macroglobulinemia
Principal Investigator:Sheeba K. Thomas
Treatment Agent:Pomalidomide
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of pomalidomide that can be given to patients with relapsed or refractory WM.
The safety of this drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma; Myeloma
Phase of Study:Phase I
Treatment Agents:Pomalidomide
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:no hospitalization
Supported By:Celgene Corporation
Return Visit:Return to clinic visits will occur once a week during the first cycle and
monthly thereafter.
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sheeba K. Thomas
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults